Science, the state, and the city : Britain's struggle to succeed in biotechnology
著者
書誌事項
Science, the state, and the city : Britain's struggle to succeed in biotechnology
Oxford University Press, 2016
1st ed
- タイトル別名
-
Science, the state, & the city
大学図書館所蔵 全1件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Bibliography: p. [229]-240
Includes index
内容説明・目次
内容説明
The book examines the evolution of one of the most important technologies that has emerged in the last fifty years: biotechnology - the use of living organisms, or parts thereof to create useful products and services.
The most important application of biotechnology has been in medicine, in the development of new drugs. The central purpose of the book is to explain how firms based in the US took the lead in commercialising the technology, and why it has been so difficult for firms in other countries to match what the leading American companies have achieved. The book looks at the institutions and policies which have underpinned US success in biotechnology. This is the US innovation "ecosystem," and it is made
up of several interlocking elements which constitute a powerful competitive advantage for US biotechnology firms. These include, a higher education system which has close links with industry, massive support from the Federal government for biomedical research, and a financial system which is well
equipped to support young entrepreneurial firms in a science-based industry.
In the light of US experience the book examines in detail the performance of UK biotechnology firms over the past forty years, starting with the creation of the UK's first dedicated biotech firm, Celltech, in 1980. The book shows how the UK made a promising start in the 1980s and 1990s but failed to build on it. Several leading firms failed, and after an initial burst of enthusiasm investors lost confidence in the British biotech sector. It is only the last few years that the sector has staged
a revival, attracting fresh investment from the US as well from the UK.
The story told in this book, based on extensive interviews with industry participants, investors, and policy makers in the UK, Continental Europe, and the US, sheds new light on one of the central issues facing governments in the advanced industrial countries - how to create and sustain new science-based industries.
目次
- 1. A New Way of Making Medicines
- 2. The US Takes the Lead
- 3. The British Response
- 4. Investors Retreat
- 5. A Second Chance for UK Biotech
- 6. Learning from the US: An International Comparison
- 7. The Financing of Biotech
- 8. The Role of Government
- 9. The Persistence of Industrial Leadership
「Nielsen BookData」 より